Literature DB >> 9893103

Natural history of myocardial infarction and angina pectoris in a general population sample of middle-aged men: a 16-year follow-up of the Primary Prevention Study, Göteborg, Sweden.

A Rosengren1, L Wilhelmsen, M Hagman, H Wedel.   

Abstract

OBJECTIVES: Although many studies have described prognosis in patients with coronary heart disease (CHD), few have compared outcome in men with clinical evidence of CHD with healthy men from the general population over an extended follow-up. This study aimed to compare long-term prognosis in men with a history of myocardial infarction (MI) and in men with angina pectoris (AP) without MI, with men without clinical signs of CHD.
DESIGN: Longitudinal general population study.
SETTING: City of Göteborg, Sweden.
SUBJECTS: From a general population sample, 195 men who had survived an MI for 0-19 years (median 3 years) and 314 men with AP but no MI (uncomplicated AP) at baseline in 1974-77 were identified and compared with 6591 men without clinical coronary disease. All were aged 51-59 years. Incident non-fatal and fatal cases occurring until the beginning of 1983 were also followed (n = 317). MAIN OUTCOME MEASURES: Death from CHD, from other causes and from all causes during a follow-up of at least 16 years.
RESULTS: Overall survival was 72% amongst men without coronary disease, 53% amongst men with uncomplicated AP and 34% amongst men with past MI at baseline. In survivors of MI the risk-factor-adjusted relative risk (RR) of coronary death during follow-up was 6.67 (95% confidence interval (CI) 5.29-8.39), of dying from non-cardiovascular causes 1.35 (0.96-1.91), and of dying from any cause 3.20 (2.67-3.83). During the first 4 years after the baseline examination, the adjusted RR of CHD death was 15.96 (10. 29-24.74), and of dying from any cause 5.22 (3.68-7.41). During the last 4 years of follow-up, relative risk was still 5.87 (3.44-10.01) for CHD death and 2.93 (2.05-4.18) for death from any cause. In men with uncomplicated AP, the adjusted relative risk of CHD death during the first 4 years was 4.05 (2.27-7.22) and 3.23 (2.10-4.96) during the last 4-year period. After the first year, the incident MI cases had the same average annual mortality (about 5%) as the prevalent cases.
CONCLUSIONS: In survivors of MI, mortality risk remained high even after an extended follow-up. Men with angina had a better prognosis, but still a compromised survival compared with the general population.

Entities:  

Mesh:

Year:  1998        PMID: 9893103     DOI: 10.1111/j.1365-2796.1998.00394.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  19 in total

1.  Summary of scientific evidence.

Authors: 
Journal:  Occas Pap R Coll Gen Pract       Date:  2002-02

2.  A population study of the long-term consequences of Rose angina: 20-year follow-up of the Renfrew-Paisley study.

Authors:  N F Murphy; S Stewart; C L Hart; K MacIntyre; D Hole; J J V McMurray
Journal:  Heart       Date:  2006-06-28       Impact factor: 5.994

3.  Chest pain and angina pectoris - or the ugly swan and the beautiful duckling.

Authors:  C van Tellingen
Journal:  Neth Heart J       Date:  2010-11       Impact factor: 2.380

4.  A Cost-Effectiveness Analysis of Surgery for Middle-Aged Men with Severe Obstructive Sleep Apnea Intolerant of CPAP.

Authors:  Kelvin B Tan; Song Tar Toh; Christian Guilleminault; Jon-Erik C Holty
Journal:  J Clin Sleep Med       Date:  2015-04-15       Impact factor: 4.062

5.  Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling.

Authors:  Marcello Lucchese; Oleg Borisenko; Lorenzo Giovanni Mantovani; Paolo Angelo Cortesi; Giancarlo Cesana; Daniel Adam; Elisabeth Burdukova; Vasily Lukyanov; Nicola Di Lorenzo
Journal:  Obes Facts       Date:  2017-06-10       Impact factor: 3.942

Review 6.  Angina (chronic stable).

Authors:  Laurence O'Toole
Journal:  BMJ Clin Evid       Date:  2008-10-01

7.  Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China.

Authors:  Miao Wang; Andrew E Moran; Jing Liu; Pamela G Coxson; Paul A Heidenreich; Dongfeng Gu; Jiang He; Lee Goldman; Dong Zhao
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-01-14

8.  The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy.

Authors:  Alain J Nordmann; Murray Krahn; Alexander G Logan; Gary Naglie; Allan S Detsky
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: New data from extended follow-up of the International Verapamil/Trandolapril Study (INVEST).

Authors:  David E Winchester; Rhonda M Cooper-Dehoff; Yan Gong; Eileen M Handberg; Carl J Pepine
Journal:  Clin Cardiol       Date:  2013-05-29       Impact factor: 2.882

10.  Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors.

Authors:  Carlo B Giorda; Angelo Avogaro; Marina Maggini; Flavia Lombardo; Edoardo Mannucci; Salvatore Turco; Stefania Spila Alegiani; Roberto Raschetti; Mario Velussi; Ele Ferrannini
Journal:  Diabetes Care       Date:  2008-09-09       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.